NCT04314544 — "Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)" trial site landscape

Public-registry site landscape for NCT04314544, “Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)”, a Active Psoriatic Arthritis study sponsored by Sun Pharmaceutical Industries Limited. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT04314544 (registry record)
Study title	Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Official title	A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Sponsor	Sun Pharmaceutical Industries Limited
Condition(s)	Active Psoriatic Arthritis
Phase	PHASE3
Listed sites	97
Site countries	United States, Canada, Czechia, Estonia, Germany, India, Italy, Poland, Slovakia, South Korea, Spain, Taiwan

Patient-friendly overview of this study: eichor.com/study/NCT04314544.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT04314544 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →